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Long noncoding RNAs are emerging as key players in various fundamental biological processes. We highlight the
varied molecular mechanisms by which lncRNAs modulate gene expression in diverse cellular contexts and their
role in early mammalian development in this review. Furthermore, it is being increasingly recognized that altered
expression of lncRNAs is specifically associated with tumorigenesis, tumor progression and metastasis. We discuss
various lncRNAs implicated in different cancer types with a focus on their clinical applications as potential
biomarkers and therapeutic targets in the pathology of diverse cancers.
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The ‘Central Dogma’ of life describes the flow of genetic
information from DNA to proteins involving RNA as an
intermediate. The view of DNA being the store house
of genetic information and proteins as its functional
manifestation dominated the field of biology for several
decades. However, the proposal of the famous RNA world
hypothesis marked the beginning of an era where RNA
was attributed more recognition in terms of cellular and
physiological functionality rather than being considered
only as a messenger between DNA and proteins [1]. After
the completion of Human Genome Project it became
evident that only a small portion of the genome encodes
proteins [2, 3]. Further, advancements in tiling array and
high throughput analyses revealed that the mammalian
genome is pervasively transcribed [4, 5] and it was
speculated that the large number of noncoding RNAs may
reflect transcriptional noise. However, recent developments
in the field of RNA biology have consolidated the fact that
noncoding RNAs (ncRNAs) are indeed crucial molecules
playing diverse regulatory roles in development and
disease. On the basis of their main biological functions,
ncRNAs are broadly classified as structural and regulatory
ncRNAs. Structural ncRNAs have been known since a* Correspondence: mrsrao@jncasr.ac.in
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of the protein synthesis machinery [6]. These include
transfer RNA (tRNA), ribosomal RNA (rRNA), small
nuclear RNA (snRNA) and small nucleolar RNA (snoRNA).
Regulatory ncRNAs include small interfering RNA (siRNA),
microRNA (miRNA), piwi-RNA (piRNA) and long non-
coding RNA (lncRNA) [7–9]. LncRNAs are arbitrarily
defined as non coding transcripts of more than 200 nt in
length. Most lncRNAs annotated till date have been re-
ported to lack protein coding capacity, albeit few of them
have the capacity to code for small peptides that had not
been identified previously [10]. Based on their genomic
location, lncRNAs are classified as sense lncRNA (lncRNA
sequence overlapping with the sense strand of a protein
coding gene), antisense lncRNA (lncRNA sequence over-
lapping with the antisense strand of protein coding gene),
bidirectional (lncRNA sequence located on the opposite
strand of a protein coding gene), intronic (lncRNA derived
from an intron of a gene) and intergenic (lncRNA derived
from region between two genes). In the present review we
focus on the general features of lncRNA, their mechanisms
of action and their role in development and cancer.Similarities and differences between lncRNA and mRNA
Irrespective of the major differences between mRNA
and lncRNA with reference to their protein coding
capacity, they share some common features as well. Similarrticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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machinery and actively transcribed lncRNA genes possess
histone modification signatures similar to that of protein
coding genes [11, 12]. The ‘K4-K36 domain’ that refers to
the distinctive chromatin signature of H3K4me3 modifica-
tion at the promoters and H3K36me3 modification along
the gene body of RNAPolII transcribed genes is present on
a host of non-protein coding multi-exonic transcripts [11].
Furthermore, majority of lncRNAs are also polyadenylated
and the pathway of biogenesis of lncRNA and mRNA
cannot be distinguished from each other [13]. Studies
have also revealed similarities between lncRNA and
the 3’UTR region of mRNA mainly with respect to
their secondary structures, sequence composition and
thermodynamic parameters [14, 15]. Sequence conserva-
tion is a feature that distinguishes lncRNA and protein
coding RNA. Many studies including recent lncRNA data-
sets identified from different species have shown the poor
conservation of lncRNA sequences across species as com-
pared to protein coding genes [16–18]. However, within
their sequence, many lncRNAs have regions which exhibit
very high conservation suggesting that key functional
domains may be the ones that retain their identity over
the evolutionary time period.
Regulation of gene expression by lncRNAs
It is being increasingly recognized that lncRNAs play a
critical role in modulating genetic networks and signal
transduction pathways during development and their
deregulation leads to disease phenotypes [19, 20]. Several
molecular mechanisms have been delineated for lncRNA
mediated regulation of gene expression [21]. These molecu-
lar mechanisms include a) LncRNAs acting as decoys by
binding to transcription factors and preventing the binding
of these factors to their regulatory DNA elements [22]; b)
Formation of triple helix with target DNA sequences [23];
c) LncRNAs titrating out miRNAs from their regulatory
mRNA targets by binding to the specific miRNAs (miRNA
sponge mechanism) [24]; d) LncRNAs as scaffold, which is
one of the most common mechanisms employed by diverse
lncRNAs [25, 26], e) LncRNAs acting as tethers to recruit
protein partners resulting in the formation of functional
ribonucleoprotein complexes [27]; f) Modulation of mRNA
translation [28]; g) Modulation of splicing [29] and h)
mRNA degradation [30]. Further, lncRNAs can serve as
precursors for small RNAs like piRNAs, miRNAs or
snoRNAs which can further perform their regulatory
functions [31–33]. Other than their regulatory role in gene
expression, lncRNAs also contribute to the organization
of different nuclear structures [34, 35]. These mechanisms
are pictorially depicted in Fig. 1. Besides, lncRNAs broadly
regulate gene expression at epigenetic, transcriptional, post
transcriptional levels and by cell-cell signaling through
hormones as discussed below.Epigenetic mode of gene regulation by lncRNAs
A large number of lncRNAs remain in the nucleus and
play an essential role in shaping the epigenome either by
genomic imprinting or through chromatin remodeling
as described below.
By genomic imprinting
Genomic Imprinting refers to the phenomenon of epi-
genetic silencing of an allele inherited from either of the
parents [36]. Short stretches of DNA known as Imprinting
Control Regions (IRCs) play a critical role in imprinting of
multiple genes [37]. Interestingly, it has been observed
that the imprinted regions show significant association
with ncRNAs, which mediate the silencing by diverse
mechanisms like chromatin remodeling and enhancer
competition [38].
Through chromatin modifying complexes
The principal means by which most of the lncRNAs
regulate gene expression is by recruiting chromatin
remodelers to facilitate histone modifications at specific
gene loci either for the repression or activation of the
target genes [39]. Various lncRNAs have been shown to
employ chromatin modifying complexes like Polycomb
Repressive Complexes 1 and 2 (PRC1 and PRC2) [40–43],
CoREST (CoRepressor for element-1-silencing transcrip-
tion factor) [44], SMCX (Smcy homolog, X-linked), [45],
G9a [46], LSD1 (Lysine Specific Demethylase 1) [47],
Trithorax (Trx) activating complex [48], etc. to regulate
gene expression, as discussed in detail later in this review.
Transcriptional regulation of gene expression by lncRNAs
Recent studies have elucidated the fact that several
lncRNAs modulate gene expression by specifically asso-
ciating either at the promoters or the enhancers of their
target genes.
Promoter-associated lncRNAs (plncRNAs/ pRNAs)
Divergent transcription at the promoter regions of various
genes gives rise to lncRNAs which in turn regulate the
transcription of the neighboring genes [49–52]. For
example, Hung et al. [53] studied the chromatin landscape
around transcription start site (TSS) of 56 cell cycle
associated genes and showed that 49 of these genes
are associated with at least one lncRNA. One of these,
PANDA (Promoter of CDKN1A Antisense DNA Damage
Activated RNA), produced from the CDKN1A promoter
region, shows p53 dependent induction after DNA
damage and aids in cell proliferation by inhibiting the
apoptotic genes [53]. Further, Negishi et al. [54] reported a
novel lncRNA, APTR (Alu-mediated p21Transcriptional
Regulator) that represses the transcription of CDK inhibi-
tor p21 by recruiting PRC2 complex to the p21 promoter.
LincRNA-p21 is another promoter associated lncRNA
Fig. 1 Diverse mechanisms of lncRNA function. Various studies have elucidated different mechanisms of function by lncRNA. One example of
lncRNA for each mechanism is mentioned in the bracket. a) LncRNAs can function as decoys by binding to a transcription factor and preventing
its action on the target DNA. b) LncRNAs modulate gene expression by recruiting chromatin modifiers. c) LncRNAs regulate various biological
processes by being a part of RNP component, regulating the activity or localization of a particular protein and playing a structural role in organization
within the nucleus. d) LncRNAs act as miRNA sponges by titrating the miRNAs away from their mRNA targets. e) LncRNAs modulate the translation
and degradation of their mRNA targets. f) LncRNA can modulate the splicing of pre-mRNA. lncRNA, long non coding RNA; mRNA, messenger RNA;
RNP, Ribonucleoprotein
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localized to promoters of genes that are repressed by p53,
facilitating their inhibition through hnRNP-K [55, 56].
Enhancer-associated lncRNAs (elncRNAs/ eRNAs)
Enhancers are critical regulatory elements required for
the tight developmental and tissue specific regulation of
gene expression and hence it is not surprising that the
number of enhancers in mammalian genome far exceeds
the number of protein coding genes [57, 58]. Very recently,
several studies have revealed that enhancers give rise to
lncRNAs that are suggested to be crucial for mediat-
ing gene regulation, both positively and negatively, by
mediating chromosomal looping [59–63]. Additionally,
super enhancers have been reported which consist of clus-
ters of enhancers, mainly associated with genes involved in
maintenance of cell identity [64, 65]. Super enhancers arealso known to be associated with lncRNAs. For example
the lncRNA, CCAT-1 L (Colorectal Cancer Associated
Transcript 1-Long isoform) transcribed from an up-
stream super enhancer locus of the oncogene, Myc
(Myelocytomatosis) functions as an eRNA and plays a
role in transcription regulation of Myc [66].
Post transcriptional regulation
LncRNAs are also widely implicated in the post tran-
scriptional regulation of mRNAs including splicing,
transport, translation and degradation. For example,
MALAT1 is involved in splicing events [67], discussed in
detail later. Certain other lncRNAs have been implicated in
stabilizing and promoting the translation of mRNAs by
extended base pairing with them [68]. In addition,
lncRNAs can also facilitate the inhibition of mRNA trans-
lation or decay by partial base pairing with the 3’UTR
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manner [30].
Regulation through hormone responsive genes
Some lncRNAs regulate gene expression through their
interaction with hormone receptors. For example,
SRA (Steroid receptor RNA Activator) lncRNA is a
coactivator of various steroid hormone receptors like
GR (Glucocorticoid Receptor), AR (Androgen Receptor),
ER (Estrogen Receptor) and PR (Progesterone Receptor)
[69]. GAS5 is another lncRNA that participates in hormone
mediated gene regulation [22].
LncRNAs in early mammalian development
Widespread studies have established that lncRNAs par-
ticipate in a variety of mammalian developmental pro-
cesses like regulating lineage commitment and cell fate
decisions, in organogenesis, in imprinting of alleles
during early development and also in specification of the
body pattern. A majority of the lncRNAs exhibit a
tissue-specific expression pattern [12], which helps in
fine tuning and coordinating the context-dependent
signals to regulate the cellular physiology when compared
to the more ubiquitously expressed protein molecules.
Interestingly, many of the lncRNAs involved in regulating
development contribute to various disease pathologies
including cancer, when altered [70, 71]. Recent studies
have identified cancer stem cells as the main players that
drive cancer progression in most cases. Cancer stem cells
bear striking similarities with the on setters of development
i.e., embryonic stem cells. Both these type of cells possess
unlimited proliferative capacity and harbor the potential to
migrate to specific destinations by undergoing epithelial to
mesenchymal transition. Under such circumstances, it
would be worthwhile to study how the multitude of
lncRNAs that govern developmental cues can also lead to
various disorders, developmental in nature or otherwise.
Dosage compensation
An excellent example of genome level regulation has been
provided by the discovery of XIST (X inactive-specific
transcript). Being involved in inactivating one of the pair
of X chromosomes, its expression is restricted mainly to
females and further only from the X-chromosome that
will be inactivated in the future [72]. Analysis of the
conservation pattern between mouse and human XIST
reveals identical stretches of sequences with interspersed
non-conserved regions, suggesting that over evolution,
principle functional domains have been retained. The
locus has been shown to transcribe a couple of lncRNAs
including REPA and TSIX. While REPA is derived from
XIST and acts to recruit the PRC2 complex to inactivate
the future Xi (inactive X chromosome) via H3K27 tri-
methylation of the chromatin [73], TSIX is the antisenserepressor of XIST and prevents inactivation of the future
Xa (active X-chromosome) [74]. Like the negative regula-
tor of XIST, there exists a positive regulator, JPX, that in
turn is produced from the X-inactivation center and
exerts its action in trans to activate XIST on Xi [75].
This TSIX-JPX switch for Xa-Xi provides a wonderful
illustration of RNA-based transcriptional control.
Loss of function studies for XIST further emphasize its
importance in mammalian development. Marahrens et al.
[76] generated a targeted partial deletion of the Xist gene
and interestingly discovered that mutant males were
unaffected by the deletion along with mutant females who
inherited the deleted gene maternally. However, mutant
females containing the paternally inherited deletion showed
death early during embryogenesis. This was attributed to
the expression of both X chromosomes in the extra-
embryonic tissues that led to abnormalities in the develop-
ment of the embryo proper.
Patterning of the body axes
The specification of the anterior-posterior body axis and
determination of the positional identity of individual cells
as well as organs is governed by a group of homeodomain
containing proteins, encoded by the Hox clusters of genes.
LncRNAs have been associated with this phenomenon, a
predominant one being HOTAIR [77]. It represents a clas-
sical example of the trans mode of action of lncRNAs as it
is expressed from the HoxC locus in mammals but exerts
its action at the HoxD locus. HOTAIR recruits the PRC2
complex at the target locus resulting in spreading of
H3K27 trimethylation over the region and additionally
interacts with the LSD1/REST/co-REST complex to per-
form lysine 4 demethylation, exemplifying the functioning
of lncRNAs as molecular ‘scaffolds’ [25]. The Hox locus is
in fact quite a storehouse of lncRNAs. HOTTIP is
expressed at the 5’ end of the HoxA locus and recruits the
WDR5/MLL complex across the locus by chromosomal
looping, bringing about H3K4 trimethylation and subse-
quent gene transcription. Interestingly, its strength of ac-
tion on the Hox genes decreases with increasing distance
from its own site of transcription [78]. While HOTTIP
has a more distal pattern of expression, another lncRNA
at the HoxC locus, FRIGIDAIR has a function in anterior
patterning [21]. The complex interplay between proteins
and lncRNAs at such gene loci at the Hox loci is thus cru-
cial in proper embryonic development.
Targeted deletion at the Hotair locus has revealed
that the lncRNA is as essential as the HOX proteins
for the proper development of the embryo [79]. Its
absence leads to malformation of the skeletal system,
massive derepression at several loci including that of
HoxD and certain imprinted loci like Dlk1, Igf2 (paternally
imprinted) and H19, Meg3 (maternally imprinted) amongst
others. Perturbations in these genes further alters gene
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development.
Genomic imprinting
LncRNAs have also been implicated in genomic imprint-
ing of specific alleles, a phenomenon that is a part of the
early developmental regime. AIR (Antisense Igf2r RNA) is
expressed in an antisense direction from the Igf2r
(Insulin-like growth factor type2 receptor) locus, is
maternally imprinted and assists in the imprinting of cer-
tain paternal genes like Slc22a2 and Slc22a3, expressed
upstream from Air [80]. Early during embryonic develop-
ment, in the placenta, AIR acts at the Slc22a3 promoter
but not at the Igf2r promoter, by interacting with H3K9
methyl transferase, G9a [81]. KCNQ1OT1 is another
example of a lncRNA participating in allelic imprinting.
Being maternally imprinted and paternally expressed anti-
sense to the Kcnq1 locus, it is involved in gene repression
at various loci in the paternal genome that have been
classified as ubiquitously imprinted (Kcnq1, Cdkn1c, Phlda2
and Slc22a18) or placental-specific imprinted (Osbpl5,Tssc4
and Ascl2) [82]. The lncRNA interacts with both G9a and
PRC2 components to bring about imprinting as early as 3.5
to 5.5 dpc of embryonic development thereby playing
an important role in specifying parental-specific gene
expression [83].
LncRNA H19 is also involved in allelic imprinting,
being expressed from the Igf2 locus and itself being
paternally imprinted [84, 85]. It is highly expressed
from the maternal allele during the blastocyst stage
and later in endodermal and mesodermal tissues, but
is restricted in expression only to skeletal tissues in the
adults [84]. Knockout of the H19 gene results in mutant
animals that are viable and fertile, showing an overweight
phenotype probably due to a gain of biallelic expression of
the previously imprinted Igf2 locus [85]. At the IGN
(Imprinted Gene Network) locus, H19 acts to repress
several genes including Igf2, Slc38a4 and Peg-1 by inter-
acting with the methyl-CpG-binding domain protein,
MBD1 [86]. The recruitment of this mediator protein to
the IGN loci directs imprinting by bringing additional
histone methyltransferases that drive repression of gene
expression. Further, H19 acts as a precursor for the micro-
RNA miR-675 that regulates placental growth [86].
LncRNAs have been well characterized in many cellular
contexts and shown to help in maintenance of pluripo-
tency of stem cells, in adult progenitor cell proliferation as
well as in the differentiation of specific tissues [87–93].
Furthermore, their involvement in early mammalian
development and in human diseases like cancer un-
derlines their importance as an integral component of
the pathways that regulate diverse physiological pro-
cesses [94]. In view of this, the role of lncRNAs in
cancer would be dealt with in detail in the upcomingsection with special focus on their clinical and therapeutic
relevance.
LncRNAs in cancer
Cancer arises due to accumulation of genetic and epigen-
etic alterations in cells. Gain or loss of chromosomes has
also been frequently observed in cancer cells. Several sig-
nal transduction pathways like Wnt/ β Catenin, MAPK,
TGFβ, p14ARF/p53, PI3K/ AKT etc. are altered in the
malignant cells which seem to produce their own growth
factors and attain replicative immortality, enhanced angio-
genesis and proliferation. Further, they evade growth
repressors, escape apoptosis and acquire the ability of
metastasis and invasion [95]. Transcriptome profiling of
tumor cells has elucidated a central role for the vast non-
coding landscape of the human genome in tumorigenesis.
Specifically, long noncoding RNAs are emerging as key
players in genetics and pathogenesis of cancer and their
dysfunction is closely associated with cancer development,
progression and metastasis; reviewed in [96–104]. While
some lncRNAs are oncogenic by nature and drive cancer
conditions when up-regulated, some others act as tumor
suppressors and cause cancer only when they are down-
regulated [105]. Some of the important lncRNAs deregu-
lated in cancer, their mechanism of action and their
potential clinical applications are discussed below.
H19 is among the earliest lncRNAs discovered and
identified to be key factor regulating gene expression
[106]. Expression of H19 is developmentally orchestrated
and in turn it determines the repression of multiple genes
through genomic imprinting [107, 108]. Interestingly, this
lncRNA itself is produced from a paternally imprinted,
maternally expressed gene at 11p15.5 locus, adjacent to
the oppositely imprinted IGF2 (Insulin like Growth
Factor2) gene. It produces a 2.3 kb spliced, capped and
polyadenylated lncRNA conserved between rodents and
human and also is processed to an miRNA, miRNA-675
[109]. A recent study by Monnier et al. [86] has shown that
H19 silences the genes in the Imprinted Gene Network
(IGN) through MBD1 (Methyl CpG-binding domain
protein1), which is responsible for the repressive histone
mark H3K9me3. Though the knockout of H19 is not lethal
in mice [110], its over-expression, either due to loss of
imprinting (LOI) at H19 locus or due to the loss of tumor
suppressor gene p53 [111], or under the influence of the
oncogene, Myc [112], leads to the activation of genes
involved in angiogenesis, cell survival and prolifera-
tion [113, 114], triggering several malignancies like
liver [115, 116], breast [117], colorectal [118], esopha-
geal [119], lung [120], pancreatic [121], gastric [122],
bladder [123] and cervical [124] carcinomas suggest-
ing an oncogenic function for this RNA. In fact level
of H19 expression shows significant correlation with
tumor grade and is a potential biomarker for various
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miRNA derived from H19, exhibits antagonistic behavior
and functions as a tumor suppressor by repressing the
IGF1R (Insulin like Growth Factor 1 Receptor) expression
[127], thus the levels of these two transcripts help in main-
taining cellular homeostasis.
KCNQ1OT1 (KCNQ1 Overlapping Transcript 1) is
another imprinted, paternally expressed 91.5 kb transcript
produced from the KCNQ1 locus, a few hundred kilo-
bases away from H19 [128]. It regulates gene expression
epigenetically by interacting with chromatin remodeling
complexes like PRC1, PRC2 and G9a to bring about
silencing of the KCNQ1 locus [129–131]. It is a cis
regulatory RNA, the aberration of which is associated
with Beckwith-Wiedemann syndrome (a congenital
overgrowth syndrome) [132, 133], colorectal cancer
[129], hepatocellular carcinoma [134] and pediatric
adrenocortical tumors [135].
ANRIL (Antisense Noncoding RNA at INK4 Locus), also
known as p15AS, is an antisense transcript of CDKN2B
gene at the 9p21.3 locus. It has several alternatively
spliced isoforms including 3.9 kb and 34.8 kb transcripts
[26, 136, 137]. Misexpression of ANRIL is associated with
a variety of diseases including cancer [138–140]. ANRIL
brings about changes in gene expression by epigenetic
means as it binds to both PRC1 and PRC2 and mediates
gene silencing at the INK4b-ARF-INK4a locus [26]. It spe-
cifically associates with SUZ12, (Suppressor of Zeste 12
homolog), a subunit of PRC2, and mediates the repression
of p15, a tumor suppressor gene [26], and consequently
inhibition of ANRIL induces p15, resulting in reduced cell
proliferation.
XIST (X-inactive-specific transcript, ~17 kb), one the
earliest lncRNAs to be discovered [27], is expressed
mainly in female somatic cells. It is transcribed from the
Xic (X inactivation Center) on the X chromosome and
spreads along and coats the chromosome from which it is
transcribed in order to epigenetically silence it in cis by
recruiting PRC2 [72, 141–144], thus achieving dosage
compensation in males. Deregulation of XIST leads to loss
or gain of X chromosomes resulting in a variety of
female, male and non sex specific cancers [145–147],
demonstrating the participation of lncRNAs in maintaining
genomic stability. In female cancers like breast, ovarian
and cervical cancers, the inactive X chromosome (Xi or
the Barr body) is conspicuously absent in the malignant
cells, while its duplication was also observed in some cells
[148], due to XIST deregulation. Further, a majority of
female cancer cell lines exhibited multiple copies of the
active X chromosome (Xa), which is acquired either due to
duplication of Xa or due to reactivation of Xi [147].
In fact the aberrant expression of XIST results not only in
aberrant ploidy of X chromosomes but also in the increased
resistance of cancer cells to chemotherapy [145].Interestingly, XIST is expressed in males also, specifically
in the transcriptionally inactive XY body in spermatocytes
[149], though it does not seem to be required for the
inactivation of XY body since male mice lacking XIST
undergo normal spermatogenesis and silencing of X linked
genes [150]. Notably, Xist is known to be over-expressed in
Testicular Germ Cell Tumors (TGCTs) and also in
patients with Klinefelter’s syndrome (47XXY). In both these
cases, super numerical X chromosomes were observed
which is suggested to contribute to oncogenesis [151, 152].
Moreover, XIST RNA is detectable in the plasma of such
patients and has emerged as a serum biomarker for both
these disease conditions [153, 154]. X chromosomal dupli-
cations were also frequent in normal XY men with male
breast cancer [155, 156].
Not only in male and female cancers, XIST is implicated
in sex independent cancers as well, mainly in lymphomas
and leukemias. Expression of XIST is lost is these cancers
resulting in extra active X chromosomes in both male and
female patients of non-Hodgkin lymphoma [157–159].
Thus, lncRNAs not only play an essential role in the regu-
lation of individual genes but they also control the copy
number of chromosomes as well.
HOTAIR (HOX Transcript Antisense Intergenic RNA)
is a 2.2 kb lncRNA produced from the HOXC gene cluster
on chromosome 12 (12q13.13) and is involved in the trans
silencing of genes at HOXD locus on chromosome 2
[25, 77]. It provides a typical example of lncRNA
regulation of gene expression through the chromatin
remodelers. It serves as a scaffold to anchor multi-
protein complexes and has a remarkable ability of
binding to distinct chromatin repressors. Specifically,
its 5’ end binds to PRC2 while its 3’ end binds to
LSD1 (Lysine Specific Demethylase 1A), which in turn
interacts with CoREST (Co-Repressor for Elements-1-
Silencing Transcription factor) and REST (Repressor
for Elements-1- Silencing Transcription factor), setting
off long term epigenetic silencing of target chromatin
region through H3K27Me3 mark [25, 77].
HOTAIR is known to repress several tumor and
metastasis suppressor genes like HOXD10 (Homeobox
D10), PGR (Progesterone Receptor), PCDH10 (Proto-
cadherin10), PCDHB5 (Protocadherin Beta 5), JAM2
(Junctional Adhesion Molecule 2), etc. [160–162]
and therefore its up-regulation leads to a variety of
malignancies like primary/ metastatic breast cancers
[161, 163–165], hepatocellular [166–168], colorectal
[162], gastrointestinal [169, 170] and non-small cell lung
carcinomas [171]. It is an oncogenic lncRNA associated
with cell proliferation, invasiveness and reduced apoptosis
and thus serves as a diagnostic and prognostic marker for
multiple cancers.
While the above discussed lncRNAs are involved in
gene regulation at epigenetic level, certain other lncRNAs
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as exemplified by NEAT1 and MALAT1, the aberrant
expression of which results in cancer.
NEAT1 (Nuclear Enriched Abundant Transcript 1)
gene produces two transcripts, the 3.7 kb NEAT-1-1
short isoform and 23 kb NEAT-1-2 long isoform. NEAT1
is widely expressed across several tissues, though the
expression of long isoform is much lower as compared to
the short isoform. NEAT1 localizes to the paraspeckles in
the nucleus [172, 173] and plays a crucial role in transcrip-
tional and post-transcription regulation of gene expression
and its knockdown leads to disintegration of paraspeckles
[34]. In fact NEAT1 and NEAT2 (MALAT1) exhibit
transcription dependent binding on human genome
over hundreds of active genes. NEAT1 is induced
strongly in breast cancer cells and is also involved in
the transformation of myeloid cells into acute pro-
myelocytic leukemia (APL) [174]. Further, it is highly
upregulated in ATRA (All Trans Retinoic Acid) induced
differentiation of NB4 (APL) cells which could be inhibited
by specific siRNA for NEAT1 [174]. Silencing of NEAT1 in
Burkitts lymphoma cells results in reduced viability,
increased apoptosis and abnormal morphology suggesting
its oncogenic nature [175].
MALAT1 (Metastasis Associated Lung Adenocarcinoma
Transcript1) is another prominent lncRNA implicated
in a variety of cancers. Also known as NEAT2 (Nuclear
Enriched Abundant Transcript 2), it is a 7.5 kb RNA
transcribed from the 11q13.1 locus, expressed broadly
across various normal human tissues [67, 176]. MALAT1
undergoes post-transcriptional processing to yield a
short t-RNA like cytoplasmic mascRNA (malat1 asso-
ciated small cytoplasmic RNA) and a long MALAT1
transcript that localizes to nuclear speckles and is
involved in splicing events. It specifically localizes to
the nuclear speckles of SR (Serine Arginine) proteins,
which are required for both constitutive and alterna-
tive splicing and the levels of MALAT1 directly influ-
ence the level of phosphorylated SR proteins [29, 67].
It is over-expressed in a variety of cancers like lung
[176, 177], liver [178, 179], bladder [180, 181], pan-
creatic [182], cervical [183], breast [184], prostate
[185], colorectal [186] and uterus [187]. It is specif-
ically linked to high metastasis rate and poor prog-
nosis in non-small cell lung cancer patients [188].
Further, its overexpression is shown to bring about
cell survival, proliferation, migration and promotion
of epithelial-mesenchymal transition by activating
Wnt signaling in vitro in urothelial carcinoma [180,
181] and hence it is suggested to be involved in cell
motility. Notably, while the over expression of MALAT1
is associated with severe consequences, its knockdown
in mice is neither lethal nor shown to cause any defects
in vivo [189].Certain lncRNAs like SRA and GAS5 mediate gene
regulation through interaction with hormone receptors
and lead to cancer when deregulated, as discussed below.
SRA (Steroid receptor RNA Activator), an lnc RNA tran-
scribed from the 5q31.3 locus, 2 kb in size, is a coactivator
of various steroid hormone receptors as discussed earlier. It
has been reported that the SRA1 gene plays a dual role and
codes both for a protein (SRAP) and an lncRNA (SRA), by
alternative splicing [190–192]. The levels of this protein
and the lncRNA are suggested to impact tumorigenesis and
tumor progression by varying the expression of target genes
[98]. SRA is a part of RNA-protein (RNP) complex and
brings about the trans activation of genes through its
interaction with the AF1 domain of nuclear receptors [69].
Its over-expression and consequent deregulated hormone
signaling is associated with breast [193, 194], uterine,
ovarian [195] and prostate [190] cancers.
GAS5 (Growth Arrest Specific 5) gene at 1q25.1 locus
produces two splice variant lncRNAs and its introns also
give rise to several snoRNAs [196]. GAS5 functions as a
tumor suppressor and facilitates normal growth arrest
and apoptosis through repression of GR mediated
transcription [22, 197]. It specifically interacts with
DNA binding domain of GR and inhibits the binding
of GR to its target genes including cIAP2 (cellular
Inhhibitor of Apoptosis 2), bringing about apoptosis,
independent of other stimuli in cancer cells. Moreover,
GAS5 has also been suggested to repress progesterone
receptor and androgen receptor in a ligand dependent
fashion [22, 196]. It also mediates the inhibition of mTOR
(mammalian Target of Rapamycin), which regulates pro-
tein synthesis, cell growth and proliferation. This fact is
corroborated by the observation that anti proliferative
effect induced by Rapamycin could be repressed by silen-
cing of GAS5 in primary T cells as well as in leukemic
cells [198]. In turn, GAS5 is regulated by a negative feed-
back loop with miR-21 [199]. Down-regulation of GAS5
and/or its snoRNAs along with genetic aberrations at its
locus were found to be associated with poor prognosis in
several cancers like breast cancer [197, 200], prostate
cancer [201], leukemia [198], gastric cancer [202], cervical
cancer [203], renal cell and Bladder cancer [204, 205].
Telomere associated lncRNA, TERRA in human cancers
Telomeres, the ends of chromosomes, are composed of
a hexanucleotide repeat, TTAGGG in vertebrates which
protects and prevents end to end fusion in chromosomes
[206]. The telomere repeats shorten after each cell cycle in
normal cells which can lead to chromosome instability and
cell death [207]. Most of the cancer cells overcome this
adversity by Telomerase activity which requires ncRNAs.
The telomerase enzyme has a protein component called
TERT (Telomerase Reverse Transcriptase) and an RNA
component called TERC (Telomerase RNA Component)
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named TERRA (Telomeric Repeat containing RNA)
derived from the subtelomeric loci has recently been
identified. TERRA localizes to and brings about the
hetrochromatin formation in telomeres, a conserved
phenomenon in eukaryotic cells [209, 210]. TERRA is
suggested to be a negative regulator of telomerase
and leads to cancer when down-regulated [211, 212].
T-UCRs in human cancers
Transcribed Ultraconserved Regions (T-UCRs) are
evolutionary highly conserved sequences between ortholo-
gous regions of the human, rat and mouse genomes
[213, 214]. They give rise to transcripts of 200–779 nt in
length that show tissue specific expression. Many of the
T-UCRs show altered expression in cancers like chronic
lymphocytic leukemia [214], colorectal carcinoma [214],
neuroblastomas [215, 216], hepatocellular carcinoma [217]
and prostate cancer [218]. The T-UCRs can be targeted by
miRNAs and offer opportunities for novel therapeutic
interventions [214, 219].
While the above mentioned lncRNAs are implicated in
multiple cancers, certain other lncRNAs have so far been
linked only to specific cancer types so far as discussed
below.
HULC (Highly Up-regulated in Liver Cancer), 1.6 kb
in size, is transcribed from the 6p23.3 locus. It was
discovered by Panzitt et al. [220] with the help of
Hepato Cellular Carcinoma (HCC) specific microarray
as the most highly up-regulated lncRNA in this cancer.
Like a typical mRNA, it has two exons and a poly A tail
and strongly localizes to the cytoplasm and co-purifies
with ribosomes but does not code for any protein. It
sequesters miRNAs and is involved in the inhibition of
miRNA mediated repression. Liu et al. [221] reported that
the SNP, rs7763881 in HULC locus was significantly asso-
ciated with HCC susceptibility in HBV (Hepatitis B Virus)
carriers. Further, knockdown of CREB (cAMP response
element-binding protein) expression as well as use of a
PKA (Protein kinase A) inhibitor resulted in down regula-
tion of HULC, revealing that phospho CREB is required
for activation of HULC [222]. HULC is oncogenic in
nature and highly up-regulated in both tumors and
plasma of HCC patients but it is not detected in any other
tissues or their cancers [220]. Thus it serves as a specific
non-invasive biomarker for HCC [223]. Moreover, it is not
expressed in primary colorectal cancers but is detected in
colorectal cancers that metastasize to liver showing its
specificity for the hepatic tissue [224].
HEIH (High Expression In HCC) is a 1.6 kb oncogenic
polyadenylated transcript generated from the 5q34.3 locus.
Yang et al. [225] examined the differentially expressed
lncRNAs between HBV related HCC and normal tissues
and one of the RNAs, HEIH, was studied in detail. HEIHwas shown to play a critical role during cell cycle and
associated with EZH2 (Enhancer of Zeste Homolog 2), a
critical component of PRC2 and represses the EZH2
target genes [225]. The levels of HEIH were found to be
significantly associated with HCC recurrence and post-
operative survival of patients and thus it serves as an
independent prognostic factor [225].
PCA3 (Prostate Cancer Antigen 3; also known as DD3,
Differential Display Code3) is derived from the 9q21.22
locus, and transcribed as three alternately spliced isoforms
of 0.6 kb, 2 kb and 4 kb [226]. It is expressed at low levels
in normal prostate and highly up-regulated in >95 % of
prostate tumors, but not in any other normal or cancer tis-
sue. It is a potent biomarker detectable in urine of prostate
cancer patients with higher specificity and sensitivity as
compared to PSA (Prostate Specific Antigen) [226, 227].
PCGEM1 (Prostate Cancer Gene Expression Marker),
1.6 kb in size, derived from the 2q32 locus, it is one of the
earliest oncogenic lncRNAs discovered. It is regulated by
Androgen Receptor (AR), a transcription factor which has
a critical role in the prostate gland development [228].
PCGEM1 is highly elevated in prostate cancer, especially
in patients with a family history of prostate cancer. It pro-
motes cell growth, proliferation and inhibits doxorubicin
induced apoptosis. Overexpression of PCGEM inhibits
PARP cleavage and delays the induction of p53 and p21
resulting in increased chemo-resistance. It plays an
important role during carcinogenesis and serves as a
specific biomarker for prostate cancer [229].
PCAT1 (Prostate Cancer Associated ncRNA Transcript
1) is a 7.8 kb lncRNA transcribed from the 8q24.13 locus,
up-regulated in both metastatic and high grade localized
prostate tumors. Prensner et al. [230] identified 121 pros-
tate cancer associated transcripts (PCATs) by RNA sequen-
cing analysis of prostate cancer tissues of which PCAT1 is
the most highly up-regulated. Knock down of PCAT1 in
androgen dependent prostate cancer cell line resulted in
alteration of hundreds of genes [230]. It has also been
reported that PCAT1 has an important role to play in
double strand break repair and inhibits homologous
recombination [231]. It is a transcriptional repressor of
DNA repair genes like BRCA2 tumor suppressor and in
turn is regulated by PRC2. Overexpression of PCAT1 is
linked to increased sensitivity to PARP inhibitors due to
decrease in RAD51 foci formation [231]. PCAT1 is a
negative prognostic marker for prostate cancer [230].
These prostate specific lncRNAs are proving to be very
useful in the clinic as diagnostic and prognostic markers
in Prostate cancer since the traditional markers like PSA
have only limited prognostic value [232].
Anti-NOS2A (Anti Nitric Oxide Synthase 2A) is a
1.9 kb intronless polyadenylated lncRNA expressed in
meningomas and glioblastomas, transcribed from the
NOS2A (17q23.2) locus. It is involved in the negative
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the neuronal differentiation [233].
HOTAIRM1 is a 483 bp transcript generated from
the HOXA cluster. It is a regulator of hematopoiesis
and its down-regulation results in the inhibition of
several HOXA genes required for hematopoiesis. In
APL (Acute Promyelocytic Leukemia), differentiation
of hematopoietic precursors gets blocked at promyelocytic
stage due to chromosomal translocations involving
Retinoic Acid Receptor alpha (RAR α) gene. ATRA
(All Trans Retinoic Acid) is used to treat this condition
and HOTAIRM1 was found to be induced in ATRA
mediated differentiation of APL cells [234], showing that
its down regulation is linked to the disease phenotype.
DLEU1 and DLEU2 (Deleted in lymphocytic Leukemia
1 and 2) are two lncRNAs produced from the 13q14.3
tumor suppressor locus [235] which is deleted in lymph-
omas and hematopoitic cancers like Chronic Lympho-
cytic Leukemia (CLL) [236, 237]. DLEU1 and DLEU2
are regulated epigenetically and in turn regulate a cluster
of genes that influence NF-kB expression. Interestingly,
expression of the protein coding genes at the 13q14.3
locus is altered but they are not associated with any
SNPs, whereas the promoter regions of the two lncRNAs
exhibit demethylation/activation marks in CLL suggesting
that the lncRNAs regulate the protein coding genes in cis.
Further, DLEU2 splice variants are the precursors of cell
cycle inhibitory miRNAs, miR-15a and miR-16-1, which
are suggested to be involved in CLL [238, 239].
Apart from the individual lncRNAs associated with
cancer, several genome wide microarray analyses in
recent years have shed light upon hundreds or thousands
of lncRNAs that are deregulated in various cancers
[240–244], further corroborating the fact that lncRNAs
are important players involved in the development and
progression of cancers.
LncRNAs as potential biomarkers and therapeutic targets
LncRNAs are not only providing us with a new perspec-
tive to our understanding of disease mechanisms but also
furnishing fresh therapeutic opportunities [245–247]. In
fact lncRNAs have an advantage over protein coding
genes in that their expression is more tissue specific, thus
making them attractive as biomarkers and therapeutic
targets. LncRNAs are remarkably stable in body fluids and
tissues, proving to be valuable biomarkers in liquid
biopsies, facilitating the avoidance of invasive procedures
[105, 248, 249]. Their distribution and levels can be evalu-
ated with the help of various techniques like in situ
hybridization, qPCR, transcriptome profiling etc. [248],
which can be used to assess the disease progression and/
or recovery with a particular treatment regimen.
LncRNAs can be targeted therapeutically by a variety
of approaches including RNAi mediated gene silencing,antisense oligonucleotides, plasmid based targeting,
through small molecule inhibitors and by gene therapy
as discussed below (Reviewed in 105, [250–252].
RNAi mediated down regulation of specific lncRNAs for
therapy
RNA interference mediated silencing of genes involved
in various diseases provides a direct approach to select-
ively inhibit target molecules. This can be achieved
through different agents like siRNA (small interfering
RNAs), shRNAs (short hairpin RNAs), and miRNAs.
Even though most of the lncRNAs are known to show
nuclear localization, various studies have revealed that
they can still be targeted by RNAi mediated interven-
tion [39].
The lncRNA HOTAIR is upregulated and serves as
a diagnostic and prognostic biomarker for breast,
liver, gastro-intestinal, lung and colorectal carcinomas
[161–171, 253]. Down regulation of HOTAIR expression
by siRNA is associated with reduced viability and invasive-
ness and induction of apoptosis in breast, hepatocellular
and pancreatic cancers [167, 254, 255]. Furthermore,
knockdown of HOTAIR also enhanced the sensitivity of
cancer cells to tumor necrosis factor alpha based immune
response and also to chemotherapeutic agents like
cisplatin and doxorubicin [167]. The lncRNA PCA3 is
highly up-regulated in prostate cancer and is a potent
biomarker detectable in urine [226]. siRNA mediated
down-regulation of PCA3 significantly inhibited growth
and viability of prostate cancer cells and also reduced the
expression of AR target genes [256], suggesting it can be a
potential therapeutic target. LncRNAs PCAT1, PRNCR1,
PCGEM, PlncRNA1 and PCAT18 are also highly up-
regulated in aggressive prostate tumors and have been
suggested as biomarkers and therapeutic targets for the
same [257, 258]. siRNA/shRNA based silencing of these
lncRNAs in prostate cancer cell lines inhibited cell prolif-
eration and induced apoptosis by decrease in AR
expression [258, 259]. The lncRNAs H19, HULC, HEIH,
MVIH are highly upregulated in hepatocellular cancer and
are valuable biomarkers for the same [116, 220, 225, 260].
siRNA/shRNA mediated silencing of these transcripts
resulted in altered expression of several genes and reduced
growth of tumors in xenografts indicating they are
potential therapeutic targets [220, 225]. The lncRNAs
H19, UCA1, CUDR, HIF1A-AS are reliable biomarkers
and potential therapeutic targets for bladder cancer
[123, 261–265]. MALAT1 is a prognostic marker for lung,
gastrointestinal and several other cancers [176–188].
shRNA mediated silencing of MALAT1 inhibited the
migration and invasive potential of adenocarcinoma
cells and cervical cancer cells respectively [177, 178].
Down-regulation of MALAT1 by siRNA in HEPG2 cell
line results in reduction in tumor progression, cell motility
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lncRNA CCAT2 is up-regulated in colorectal cancer and
can be targeted by specific miRNAs [Table 1].
Although RNAi based therapeutic agents are used to
target lncRNAs in cell lines quite effortlessly, in vivo, they
would require suitable delivery vehicles like liposomes,
nanoparticles or viruses for proper cellular uptake, pre-
vention of their degradation or accumulation in liver.
Nevertheless, several RNAi based therapies are in clinical
trials [266, 267], though there is still a need for further
improvements for safe and effective remedies.
Antisense Oligonucleotides (ASO) mediated therapy
Antisense oligonucleotides are short (13–25) single
stranded DNA oligonucleotides complementary to RNA
of interest. ASOs are modified to avoid degradation by
nucleases and in turn they induce RNase H mediated
cleavage of their target transcripts. Several ASOs, mainly
those targeting mRNAs are already in advanced clinical
trials [268, 269], while two ASO based drugs to treat
Cytomegalovirus retinitis and high blood cholesterol
have already been approved by FDA [270, 271]. Similar
approaches are being developed to target cancer related
lncRNAS. Accordingly, AntagoNATs, ASOs that target
antisense lncRNA, are being employed to up-regulate
specific mRNAs/ proteins by silencing the corresponding
antisense lncRNA [272]. AntagoNATs are modified not
only in their 5’ and 3’ termini but also in their backbone
in order to make them more stable and to enhance
their cellular uptake. Thus ASOs have an advantage
over siRNAs which are usually unstable and hard to
be targeted into tumor cells in vivo [273]. Notably,
ASO (Antisense Oligonucleotide) mediated knockdown of
MALAT1 inhibited the metastasis in human lung cancer
cells in a mouse xenograft model [188]. Despite the
promise, poor cellular uptake and cytotoxicity remain
as matters of concern for ASOs.
Small molecule inhibitor mediated modulation of lncRNAs
The molecular interactions of lncRNAs with their inter-
acting protein partners can be blocked by small molecule
inhibitors that mask the binding sites on their interactors
[251]. Accordingly, the interaction of HOTAIR with PRC2
or LSD1 can be inhibited with the help of small molecular
inhibitors to reduce the metastasis in breast cancer [274].
Alternately, in another approach, small molecule inhibi-
tors or specific oligonucleotides can be designed to bind
and change the secondary structure of lncRNAs and thus
inhibit their interaction with binding partners [251, 275].
Targeting the lncRNA-protein interactions would not only
lend tissue and developmental specificity but also has an
advantage over targeting only RNAs or proteins since
lncRNAS mediate regulation of gene expression essentially
through their protein partners. Furthermore, this methodis also superior to RNAi based methods which may suffer
from off target effects. Moreover small molecules are
easier to be administered and exhibit a better cellular
uptake than ASOs, siRNAs or viral vectors. However, this
approach needs a better understanding of RNA-protein
interactions and identification of additional molecules that
target RNA.
Plasmid based therapy
In a novel therapeutic approach, a plasmid, BC-819/
DTAH19, has been developed which carries a diphtheria
toxin subunit under the regulation of H19 promoter.
When this plasmid is injected into the tumor, it brings
about the reduction in tumor size due to the production
of high level of diphtheria toxin in human trials of blad-
der cancer [276]. This method attempts to reduce the
tumor size in general rather than targeting any specific
lncRNA and has shown encouraging results in recent
times in other cancers like lung, colon, pancreatic and
ovarian cancer as well [101].
Gene therapy
Some lncRNAs are down-regulated in tumor samples as
compared to normal tissues. The lncRNA PTCSC3
(Papillary Thyroid Carcinoma Susceptibility Candidate
3) is down-regulated in thyroid tumors [277]. PTENP1,
a pseudogene of PTEN, is down-regulated in colon
carcinoma [278]. MEG3 is downregulated in meningioma
and glioma [279]. LincRNA-p21 is down-regulated in
lymphoma, lung carcinoma [56] and colorectal cancer
[280]. Delivery of beneficial tumor suppressor RNAs
can be attempted with the help of gene therapy in
such cases [247, 251].
In summary, though the above discussed means of
targeting long noncoding RNAs for cancer therapy
looks very promising in cell lines, the delivery of
therapeutic agents to their specific targets in actual
patients in vivo would be quite challenging and effect-
ive strategies need to be developed for the same
[281]. Although, trials on mouse models have shown
some hope, but many of the lncRNAs are primate/
human specific and cannot be investigated in vivo in
knockdown/ knockout models in mice. Another point
of concern is the fact that even though it has been
well established that altered expression of lncRNAs is
associated with various cancers, it has not yet been
clearly recognized whether the alteration is a cause or
consequence of the disease. This calls for a thorough
understanding of structure and mechanism of lncRNAs,
their molecular interactions and development of novel
quantitative assays to screen for drugs. Nonetheless,
lncRNAs offer new hope for novel treatment options and
in the near future it is expected that many of the lncRNAs
may end up as strong diagnostic tools for cancer detection
Table 1 List of lncRNAs associated with different cancers
LncRNA Size Locus Mechanism Nature Related cancer/ Biomarker/Therapeutic target References
ANRIL 3.9 kb, Multiple isoforms 9q21.3 Regulates CDKN2A/2B locus by recruiting
PRC1/PRC2
Oncogenic Prostate cancer, Leukemia, other diseases [26, 137–140]
anti-NOS2A 1.9 kb 17q23.2 Down regulates Nos2A Oncogenic Meningomas and Glioblastomas [233]
lncRNA-ATB 2.4 kb 14q11.2 Activated by TGF-β Oncogenic Hepatocellular carcinoma [310]
BC200 0.2 kb 2p21 Translational modulator Oncogenic Multiple cancers [283]
CCAT1 2.6 kb, 5.2 kb 8q.24 Regulates Myc by long range chromatin loops Oncogenic Colorectal, gall bladder cancer [66, 316, 317]
CCAT2 0.34 kb 8q24.21 Involved in Microsatellite stability Oncogenic Colorectal, lung, breast cancers [305, 306, 318]
CRNDE 10.3 kb, Multiple
transcripts
16q12.2 Interacts with PRC2, CoREST, regulated by
Insulin, IGF
Oncogenic Colorectal cancer, glioma [284, 285]
CUDR 2.2 kb 19p13.12 Involved in drug resistance Oncogenic Lung, cervical, colon and Bladder cancer [261, 262]
H19 2.3 kb 11p15.5 Imprinting Oncogenic Liver, esophagal, breast, bladder, Pancreatic,
colorectal, gastric, cervical
[84–86, 106–127]
HEIH 1.6 kb 5q34.3 Represses PRC2 target genes through EZH2 Oncogenic Hepatocellular carcinoma [225]
HOTAIR 2.2 kb 12q13.13 Chromatin modification by binding to PRC2, LSD1 Oncogeneic Breast, liver, lung, gastrointestinal and colorectal [160–171]
HULC 0.5 kb 6p24.3 Interactor of CREB Oncogenic Hepatocellular carcinoma [220–224]
KCNQ1OT1 91.5 kb 11p15.5 Imprinted lncRNA, binds to PRC2 & G9a Oncogenic Colorectal cancer [82, 83, 128–135]
MALAT1 ~8 kb 11q13.1 Modulates alternative splicing Oncogenic Colorectal and breast cancers [29, 67, 176–189]
NEAT1 3.7 kb, 23 kb 11q13.1 Transcriptional and Post transcriptional
regulation
Oncogenic Prostate cancer and leukemias [34, 174, 175]
ncRAN/ SNHG16 2 kb 17q25.1 Interacts with N-myc Oncogenic Bladder, colorectal cancer, neuroblastoma [286, 287]
PCA3 0.6, 2 kb, 4 kb
and 23 kb
9q21.2 AR signaling Oncogenic Prostae Cancer [226, 227, 257]
PCAT1 7.8 kb 8q24.21 Inhibits homologous recombination Oncogenic Prostate cancer [230, 231]
PCGEM 27 kb 2q32 Activates AR regulated genes Oncogenic Prostate cancer [228, 229]
PCNA-AS1 384 bp 20p12.3 Increases stability of PCNA mRNA oncogenic Hepatocellular carcinoma [311]
PlncRNA-1 24.5 21q22.12 Interacts with AR Oncogenic Prostate cancer [259]
PRNCR1 13 kb 8q24.22 Activates AR regulated genes Oncogenic Prostate cancer [288]
PVT1 >300 kb, Mutiple
transcripts
8q24 Interacts with p53 Oncogenic Liver, breast, ovarian, colorectal, gastric,
nonsmall cell lung cancer and leukemia
[289–295]
SChLAP1/ PCAT114 224.8 kb 2q31.3 Inhibits binding of SWI/SNF on genome Oncogenic Prostate cancer [296]
SRA 2 kb 5q31.3 Regulation through steroid hormones and PRC2 Oncogenic Prostate, breast, ovarian and uterine cancers [69, 98, 190–195]
TUG1 6.7 kb, splice variants 22q12.2 Interacts with PRC2 to repress target genes,
induced by p53
Oncogenic Urothelial and non small cell lung cancer [297, 298]
UCA1 1.4 kb, 2.2 kb, 2.7 kb 19p13.12 Regulates cell cycle through CREB Oncogenic Bladder and Breast cancer [312–315]
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Tumor
Suppressor
BANCR 693 bp 9q21.11 Regulates MAPK pathway Tumor
suppressor
Melanoma, retinoblastoma, lung [307–309]
GAS5/ SNHG2 Multiple lnc and
snoRNAs
1q25.1 Hormonal regulation (GR) Tumor
Suppressor
Breast, prostste, Gastric, cervical and
renal cell cancers
[22, 196–205]




Lung, liver and colorectal cancer [300]




Lymphoma, lung, colorectal carcinomas [28, 55, 56, 280]
MEG3 1.6 kb, splicing isoforms 14q32.2 Positive regulator of p53 Tumor
suppressor
Prostate, bladder, Pituitory adenocarcinomas,
meningoma
[301–304]
PTEN-P1 (Pseudogene) ~4 kb 9p13.3 Enhances PTEN expression Tumor
suppressor
Prostate, colon cancers [278]
XIST 19 kb Xq13.2 Imprinting, binds to PRC2 Tumor
suppressor
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increasing number of cancer cases and its incurable
nature, there is always a need for novel biomarkers
for diagnosis, prognosis and therapy.
Key oncogenic and tumor suppressor lncRNAs sug-
gested as potential biomarkers/therapeutic targets are
summarized in Table 1.
Conclusions and future perspectives
Cancer, being an incurable disease so far, needs novel
and effective biomarkers and therapeutic strategies. It
is becoming increasingly apparent that deregulated
lncRNAs form a new stratum of intricacy in the molecular
makeup of human diseases. Their role and mode of action
in various signaling pathways during normal and disease
conditions is being dissected meticulously and their sig-
nificance is being acknowledged widely. LncRNAs are
strongly associated with clinico-pathological outcome and
prognosis of various diseases, more particularly in cancers
and furnishing fresh therapeutic possibilities. They are
generally expressed in tissue specific manner and exhibit
aberrant expression in cancers. Therefore, targeting and
either down-regulating or up-regulating specific lncRNAs
in malignancies may not have deleterious side effects on
normal cells. Thus, of late, both academia and biotech
companies are turning their attention towards these novel
and possibly personalized treatment options and trying to
develop biological/nucleic acid drugs [282].
Various companies/organizations like RaNa Therapeutics,
CuRNA, Sarepta, Smart Therapeutics, Allen Institution for
Brain Science, Regulus, Miragen Therapeutics, Santaris
Pharma etc. are pioneering the ncRNA based medicines.
Soon we may see the time when lncRNA signature
becomes a routine diagnostic test for diverse diseases,
followed up by RNA based therapy curing the hitherto
incurable diseases like cancer.
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